XJPX
3353
Market cap66mUSD
Oct 09, Last price
2,805.00JPY
1D
0.04%
1Q
-1.51%
Jan 2017
-2.94%
IPO
40.25%
Name
Medical Ikkou Group Co Ltd
Chart & performance
P/E
8.28
P/S
0.19
EPS
338.59
Div yield, %
3.57%
Shrs. gr., 5y
0.04%
Rev. gr., 5y
10.35%
Revenues
54.98b
+13.62%
Net income
1.28b
+12.52%
CFO
1.21b
+0.81%
Dividend
Feb 25, 202760 JPY/sh
Earnings
Oct 09, 2026
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Medical Ikkou Group Co.,Ltd. is a Japanese enterprise primarily known for managing dispensing pharmacies across the nation. Beyond its extensive pharmacy operations, the company diversified its activities to include the management of various care facilities, such as nursing homes, outpatient nursing centers, and home-visit nursing care services. Its business portfolio also encompasses the wholesale of generic pharmaceuticals and real estate property rentals. Furthermore, the group is active in financial investments, including stakes in both listed and unlisted securities, and participates in merger and acquisition activities. The company currently oversees 93 dispensing pharmacy locations. Established in 1980, Medical Ikkou Group is headquartered in Tsu, Japan.
Key people
Kyosuke Oda
Senior Executive Officer , Director of Finance and IR · since 2025
Kiyoshi Hattori
President of Subsidiary, Director · since 2021
Toshiharu Sakurai
Senior Managing Director, Representative Director · since 2025
Yoshiyuki Adachi
Senior Executive Officer · since 2023
Kanichi Eguchi
Senior Executive Officer, President of Subsidiary · since 2023
Katsumi Kojima
Senior Executive Officer · since 2023
Satoshi Notsu
Senior Executive Officer · since 2025
Takamitsu Tachibana
Senior Executive Officer, General Affairs and Human Resources · since 2023
Tsuyoshi Toyama
Executive Officer, Director of Tokai Sales in Main Seibu Office Unit · since 2023
Katsumune Iwai
Senior Executive Officer, Director of Human Resources and Administration · since 2025
Masaru Sakai
Executive Officer, Director of General Affairs & Human Resources
Mitsuhiro Imamura
Executive Officer, Director of General Affairs & Audit
Tadashi Maekawa
Executive Officer, Director of Accounting · since 2022
Toshihisa Minamino
President, Group Chief Executive Officer, Representative Director · since 2025
Kunihiko Toyama
Managing Director · since 2025
Yutaka Horie
Independent Director · since 2024
Independent Director · since 2021
Shigehiro Kuwahara
Independent Director · since 2023
Sumire Sawada
Independent Director · since 2025
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑02 | 2025‑02 | 2024‑02 | 2024‑02 | 2023‑02 | 2022‑02 | 2021‑02 | 2020‑02 | 2020‑02 | 2019‑02 | 2018‑02 | 2017‑02 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||